Croda International PLC

Regulatory Filings • Oct 7, 2022

National Storage Mechanism | Additional information

RNS Number : 0923C

Croda International PLC

07 October 2022

Press Release

7 October 2022

Investor seminar

Empowering biologics delivery in Health Care

Croda International Plc ('Croda') is today hosting an investor seminar on its Health Care business, a business unit within its Life Sciences sector. The event will focus on growth opportunities in the pharmaceutical market and Croda's unique positioning as an innovator of delivery systems for complex biologic drugs. Croda expects the recent strong organic growth in its drug delivery platforms to continue (excluding Covid-19 lipid systems), supplemented by an exciting innovation pipeline which is expected to commercialise from 2025. There will be no new price sensitive information communicated at the event.  

Commenting ahead of the seminar, Steve Foots, Group Chief Executive Officer, said:

"Over the last twenty years, we have been steadily growing and investing in our Health Care business, accelerating this progress with the acquisitions of vaccine adjuvant and lipid system technologies. Today we are focused on robust, high growth and high value markets, uniquely positioned as the leading innovator of delivery systems for complex biologic drugs and vaccines. It is an exciting part of Croda with significant opportunities to drive future growth."

The event is being held at the London Stock Exchange from 08.30 to 12.00 BST. There will be a webcast of the seminar starting at 09.30 BST with a replay available afterwards. To register for the webcast, visit www.croda.com/investors.

For enquiries contact:

Investors:	David Bishop, Croda	+44 7823 874428
	Reece De Gruchy, Croda	+44 7826 548908
Press:	Charlie Armitstead, Teneo	+44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDQLFBLBLXFBL